Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases.

Mahieux R, Suspène R, Delebecque F, Henry M, Schwartz O, Wain-Hobson S, Vartanian JP.

J Gen Virol. 2005 Sep;86(Pt 9):2489-94.

PMID:
16099907
2.

Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.

Suspène R, Guétard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP.

Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8321-6. Epub 2005 May 26.

3.

APOBEC3G targets human T-cell leukemia virus type 1.

Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T.

Retrovirology. 2005 May 19;2:32.

4.

APOBEC-mediated editing of viral RNA.

Bishop KN, Holmes RK, Sheehy AM, Malim MH.

Science. 2004 Jul 30;305(5684):645.

5.

Functional central polypurine tract provides downstream protection of the human immunodeficiency virus type 1 genome from editing by APOBEC3G and APOBEC3B.

Wurtzer S, Goubard A, Mammano F, Saragosti S, Lecossier D, Hance AJ, Clavel F.

J Virol. 2006 Apr;80(7):3679-83. Erratum in: J Virol. 2008 May;82(10):5116.

6.

Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.

Armitage AE, Deforche K, Welch JJ, Van Laethem K, Camacho R, Rambaut A, Iversen AK.

J Virol. 2014 Nov;88(21):12882-94. doi: 10.1128/JVI.01460-14. Epub 2014 Aug 27.

7.
8.

APOBEC3G & HTLV-1: inhibition without deamination.

Strebel K.

Retrovirology. 2005 May 29;2:37.

9.

Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.

Rose KM, Marin M, Kozak SL, Kabat D.

AIDS Res Hum Retroviruses. 2005 Jul;21(7):611-9.

PMID:
16060832
10.

Induction of antiviral cytidine deaminases does not explain the inhibition of hepatitis B virus replication by interferons.

Jost S, Turelli P, Mangeat B, Protzer U, Trono D.

J Virol. 2007 Oct;81(19):10588-96. Epub 2007 Jul 25.

11.

Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.

Bishop KN, Holmes RK, Malim MH.

J Virol. 2006 Sep;80(17):8450-8.

12.

APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.

Suspène R, Sommer P, Henry M, Ferris S, Guétard D, Pochet S, Chester A, Navaratnam N, Wain-Hobson S, Vartanian JP.

Nucleic Acids Res. 2004 Apr 30;32(8):2421-9. Print 2004.

13.

RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study.

Bernacchi S, Henriet S, Dumas P, Paillart JC, Marquet R.

J Biol Chem. 2007 Sep 7;282(36):26361-8. Epub 2007 Jul 2.

14.

High level of APOBEC3F/3G editing in HIV-2 DNA vif and pol sequences from antiretroviral-naive patients.

Bertine M, Charpentier C, Visseaux B, Storto A, Collin G, Larrouy L, Damond F, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2015 Apr 24;29(7):779-84. doi: 10.1097/QAD.0000000000000607.

PMID:
25985400
15.

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D.

Nature. 2003 Jul 3;424(6944):99-103. Epub 2003 May 28.

PMID:
12808466
16.

Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.

Kim EY, Lorenzo-Redondo R, Little SJ, Chung YS, Phalora PK, Maljkovic Berry I, Archer J, Penugonda S, Fischer W, Richman DD, Bhattacharya T, Malim MH, Wolinsky SM.

PLoS Pathog. 2014 Jul 31;10(7):e1004281. doi: 10.1371/journal.ppat.1004281. eCollection 2014 Jul.

17.

Complementary function of the two catalytic domains of APOBEC3G.

Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR.

Virology. 2005 Mar 15;333(2):374-86.

18.
19.

Ubiquitination of APOBEC3 proteins by the Vif-Cullin5-ElonginB-ElonginC complex.

Shirakawa K, Takaori-Kondo A, Kobayashi M, Tomonaga M, Izumi T, Fukunaga K, Sasada A, Abudu A, Miyauchi Y, Akari H, Iwai K, Uchiyama T.

Virology. 2006 Jan 20;344(2):263-6. Epub 2005 Nov 21.

20.

The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains.

Bogerd HP, Wiegand HL, Doehle BP, Cullen BR.

Virology. 2007 Aug 1;364(2):486-93. Epub 2007 Apr 16.

Supplemental Content

Support Center